02:10 ETKeymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekanntprnewswire·1 day ago, 01:11 AM02162-0.44%GILD+1.38%
05:13 ETKeymed Biosciences Announces 2026 H1 Results and Business Updatesprnewswire·Aug 21 at 04:15 AM02162-0.44%GILD+1.38%
Citi Raises KEYMED BIO-B TP to HKD97.5, Rating Buy/High RiskAASTOCKS News·Aug 21 at 02:36 AM02162-0.44%
Keymed Biosciences Announces 2026 H1 Results and Business Updates | LKFT Stock NewsStockTitan·Aug 20 at 01:09 AM02162-0.44%AZN+1.77%
Keymed’s CM512 Hits Phase II Targets and Wins Breakthrough Status for Nasal Polyp TreatmentTip Ranks·Aug 9 at 07:07 PM02162-0.44%
Keymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric CancerTip Ranks·Jul 27 at 11:07 PM02162-0.44%AZN+1.77%
Keymed’s CM512 Wins China Breakthrough Status, Advances in Multiple Phase II TrialsTip Ranks·Jul 22 at 11:07 PM02162-0.44%
Keymed Biosciences advances Phase II trials for CM512 across multiple respiratory and inflammatory indicationsPUBT·Jul 22 at 11:01 PM02162-0.44%
Keymed Biosciences says China regulator grants breakthrough therapy designation for CM512 in CRSwNPPUBT·Jul 22 at 11:00 PM02162-0.44%
